Literature DB >> 16859597

Respiratory system involvement in systemic vasculitides.

P Manganelli1, P Fietta, M Carotti, A Pesci, F Salaffi.   

Abstract

The respiratory system may be involved in all systemic vasculitides (SV), although with a variable frequency. Lung disease is a very common and important feature of the antineutrophil cytoplasmic antibodies (ANCA)-associated SV (AASV), such as Wegener's granulomatosis (WG), Churg-Strauss syndrome (CSS), and microscopic polyangiitis (MPA). In WG, almost all patients have either upper airway or lower respiratory tract disease. Solitary or multiple nodules and masses are the most common findings on chest radiograph. Asthma is a cardinal symptom of CSS, often preceded by allergic rhinitis, frequently complicated by nasal polyposis and sinusitis. Pulmonary transient and patchy alveolar infiltrates are the most common radiographic findings. In MPA, diffuse alveolar hemorrhage (DAH) due to alveolar capillaritis is the most frequent manifestation of the respiratory involvement, clinically expressing with hemoptysis, respiratory distress and anemia. However, DAH may be subclinical and has to be suspected when chest radiograph demonstrates new unexplained bilateral alveolar infiltrates, in the face of falling hemoglobin levels. In giant cell arteritis, the most frequent respiratory symptom is cough, usually non-productive, persistent, and responsive to corticosteroids. In Takayasu arteritis, pulmonary involvement is frequently subclinical and detectable by non-invasive techniques. Pulmonary involvement is rare in polyarteritis nodosa, Kawasaki disease, Henoch-Schönlein purpura and cryoglobulinemic vasculitis. In conclusion, the involvement of the respiratory system is a very common and important feature of AASV, whereas is less frequent in other SV. It comprises a wide spectrum of clinical features and radiological findings, and may have a prognostic significance. The assessment of the respiratory system should be included in the work-up of all patients with SV, especially of those with AASV.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16859597

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  19 in total

1.  Henoch-Schönlein purpura: a clinical case with dramatic presentation.

Authors:  João Bento; Adriana Magalhães; Conceição Souto Moura; Venceslau Hespanhol
Journal:  BMJ Case Rep       Date:  2010-09-09

2.  Wegener granulomatosis.

Authors:  Nichole Graves
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-10

3.  Re-evaluation of 129 patients with systemic necrotizing vasculitides by using classification algorithm according to consensus methodology.

Authors:  Sevil Kamali; Bahar Artim-Esen; Burak Erer; Lutfiye Ozdener; Ahmet Gul; Lale Ocal; Orhan Aral; Murat Inanc
Journal:  Clin Rheumatol       Date:  2011-08-04       Impact factor: 2.980

Review 4.  Pulmonary vasculitis.

Authors:  Ana Casal; Juan Díaz-Garel; Tara Pereiro; María E Toubes; Jorge Ricoy; Luis Valdés
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 5.  Diffuse Alveolar Hemorrhage in Autoimmune Diseases.

Authors:  Marco Ulises Martínez-Martínez; David Alejandro Herrera-van Oostdam; Carlos Abud-Mendoza
Journal:  Curr Rheumatol Rep       Date:  2017-05       Impact factor: 4.592

6.  Pulmonary involvement in primary systemic vasculitides.

Authors:  Jean-Paul Makhzoum; Peter C Grayson; Cristina Ponte; Joanna Robson; Ravi Suppiah; Richard A Watts; Raashid Luqmani; Peter A Merkel; Christian Pagnoux
Journal:  Rheumatology (Oxford)       Date:  2021-12-24       Impact factor: 7.580

Review 7.  Bench-to-bedside review: pulmonary-renal syndromes--an update for the intensivist.

Authors:  Spyros A Papiris; Effrosyni D Manali; Ioannis Kalomenidis; Giorgios E Kapotsis; Anna Karakatsani; Charis Roussos
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

Review 8.  [Vasculitides and eosinophilic pulmonary diseases].

Authors:  C Kroegel; M Foerster; S Quickert; H Slevogt; T Neumann
Journal:  Internist (Berl)       Date:  2018-09       Impact factor: 0.834

9.  [Vasculitides and eosinophilic pulmonary diseases].

Authors:  C Kroegel; M Foerster; S Quickert; H Slevogt; T Neumann
Journal:  Z Rheumatol       Date:  2018-12       Impact factor: 1.530

10.  Intrapulmonary administration of recombinant activated factor VII in diffuse alveolar haemorrhage: a report of two case stories.

Authors:  Angel Estella; Antonio Jareño; Luis Perez-Bello Fontaiña
Journal:  Cases J       Date:  2008-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.